Athena Sudom

Athena Sudom

Auto-generated profile, based on publicly available information

Athena Sudom

Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080 USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DSDaQing Sun
DaQing Sun
ZWZhulun Wang
Zhulun Wang
SCSeb Caille
Seb Caille
MDMichael DeGraffenreid
Michael DeGraffenreid
FTFelix Gonzalez-Lopez de Turiso
Felix Gonzalez-Lopez de Turiso
JPJay P. Powers
Jay P. Powers

1 December 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
XYXuelei Yan
Xuelei Yan
ZWZhulun Wang
Zhulun Wang
ASAthena Sudom
Athena Sudom
MCMario Cardozo
Mario Cardozo
MDMichael DeGraffenreid
Michael DeGraffenreid
JPJay P. Powers
Jay P. Powers

29 December 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AKAgnieszka Kielczewska
Agnieszka Kielczewska
IDIgor D'ANgelo
Igor D'ANgelo
MAMaria Sheena Amador
Maria Sheena Amador
TWTina Wang
Tina Wang
ASAthena Sudom
Athena Sudom
IFIan N. Foltz
Ian N. Foltz
Therapeutic antibody development requires discovery of an antibody molecule with desired specificities and drug-like properties. For toxicological studies, a therapeutic antibody must bind the ortholog antigen with a similar affinity to the human target to enable relevant dosing regimens, and antibodies falling short of this affinity design goal may not progress as therapeutic leads. Herein, we report the novel use of mammalian recombination signal sequence (RSS)–directed recombination for complementarity-determining region–targeted protein engineering combined with mammalian display to close the species affinity gap of human interleukin (IL)-13 antibody 731. This fully human antibody has not progressed as a therapeutic in part because of a 400-fold species affinity gap. Using this nonhypothesis-driven affinity maturation method, we generated multiple antibody variants with improved IL-13 affinity, including the highest affinity antibody reported to date (34 fM). Resolution of a cocrystal structure of the optimized antibody with the cynomolgus monkey (or nonhuman primate) IL-13 protein revealed that the RSS-derived mutations introduced multiple successive amino-acid substitutions resulting in a de novo formation of a π–π stacking–based protein–protein interaction between the affinity-matured antibody heavy chain and helix C on IL-13, as well as an introduction of an interface-distant residue, which enhanced the light chain–binding affinity to target. These mutations synergized binding of heavy and light chains to the target protein, resulting in a remarkably tight interaction, and providing a proof of concept for a new method of protein engineering, based on synergizing a mammalian display platform with novel RSS-mediated library generation.